Beta amyloid, tau, neuroimaging, and cognition: Sequence modeling of biomarkers for Alzheimer's Disease

Brain Imaging and Behavior

Volumn 6, Issue 4, 2012, Pages 610-620

  Han, S Duke ^a,b   Gruhl, Jonathan ^c   Beckett, Laurel ^d   Dodge, Hiroko H ^e   Stricker, Nikki H ^f,g   Farias, Sarah ^d   Mungas, Dan ^d  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f VA BOSTON HEALTHCARE SYSTEM   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Beta amyloid; Executive Functions; Memory; Neuroimaging; Tau

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONTROLLED STUDY; EXECUTIVE FUNCTION; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; NEUROANATOMY; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL LOBE;

EID: 84871719595     PISSN: 19317557     EISSN: 19317565     Source Type: Journal    
DOI: 10.1007/s11682-012-9177-0     Document Type: Article

References (39)

1. Alzheimer's Association. (2009). 2009 Alzheimer's Disease facts and figures. Alzheimer's and.
2. Blom, G. (1958). Statistical estimates and transformed beta variables. New York: John Wiley & Sons, Inc.
3. Braak, H., Braak, E., & Bohl, J. (1993). Staging of Alzheimer-related cortical destruction. European Neurology, 33, 403-408.
4. Buerger, K., Ewers, M., Pirttila, T., et al. (2006). CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain, 129, 3035-3041.
5. Butterfield, D. A., Castegna, A., Lauderback, C. M., & Drake, J. (2002). Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiology of Aging, 23, 655-664.
6. Cole, D. A., & Maxwell, S. E. (2003). Testing mediational models with longitudinal data: questions and tips in the use of structural equation modeling. Journal of Abnormal Psychology, 112(4), 558-577.
7. Dale, A. M., Fischl, B., & Sereno, M. I. (1999). Cortical surface-based analysis. I. Segmentation and surface reconstruction. NeuroImage, 9(2), 179-194.
8. 18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). PNAS, 98, 10966-10971.
9. Diggle, P. J., Heagerty, P., Liang, K. Y., & Zeger, S. L. (2002). The analysis of longitudinal data (2nd ed.). Oxford: Oxford University Press.
10. Dowling, N. M., Tomazewski Farias, S., Reed, B. R., Sonnen, J. A., Strauss, M. E., Schneider, J. A., Bennett, D. A., & Mungas, D. (2010). Neuropathological associates of multiple cognitive functions in two community-based cohorts of older adults. JINS. Epub ahead of print.
11. Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., et al. (2002). Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron, 33(3), 341-355.
12. Fischl, B., Salat, D. H., van der Kouwe, A. J., Makris, N., Segonne, F., Quinn, B. T., et al. (2004). Sequence-independent segmentation of magnetic resonance images. NeuroImage, 23(Suppl 1), S69-S84.
13. Fischl, B., Sereno, M. I., & Dale, A. M. (1999). Cortical surface-based analysis. II: inflation, flattening, and a surface-based coordinate system. NeuroImage, 9(2), 195-207.
14. Fischl, B., van der Kouwe, A., Destrieux, C., Halgren, E., Segonne, F., Salat, D. H., et al. (2004). Automatically parcellating the human cerebral cortex. Cerebral Cortex, 14(1), 11-22.
15. Habeck, C., Fostern, N. L., Pernecsky, R., Kurz, A., Alexopoulos, P., Koeppe, R. A., & Stern, Y. (2008). Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. NeuroImage, 40(4), 1503-1515.
16. Hampel, H., Goernitz, A., & Buerger, K. (2003). Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and AB1-42 proteins to phosphorylated tau protein. Brain Research Bulletin, 61, 243-253.
17. Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003). Alzheimer disease in the U. S. population: prevalence estimates using the 2000 census. Archives of Neurology, 60(8), 1119-1122.
18. Howieson, D. B., Carlson, N. E., Moore, M. M., Wasserman, D., Abendroth, C. D., Payne-Murphy, J., & Kaye, J. A. (2008). Trajectory of mild cognitive impairment onset. Journal of the International Neuropsychological Society, 14(2), 192-198.
19. Ivnik, R. J., Malec, J. F., Tangalos, E. G., Petersen, R. C., Kokmen, E., & Kurland, L. T. (1990). The Auditory-Verbal Learning Test (AVLT): norms for ages 55 years and older. Psychological Assessment: A Journal of Consulting and Clinical Psychology, 2(3), 304-312.
20. Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, 9, 119-128.
21. Jack, C. R., Shiung, M. M., Gunter, J. L., et al. (2004). Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology, 62, 591-600.
22. Jacqmin-Gadda, H., Commenges, D., & Dartigues, J. F. (2006). Random change point model for joint modeling of cognitive decline and dementia. Biometrics, 62(1), 254-260.
23. Jagust, W. J., Bandy, D., Chen, K., Foster, N. L., Landau, S. M., Mathis, C. A., Price, J. C., Reiman, E. M., Skovronsky, D., Koeppe, R. A., & Investigators, A. D. N. I. (2010). The ADNI PET Core. Alzheimer's & Dementia, 6, 221-229.
24. Johnson, D. K., Storandt, M., Morris, J. C., & Galvin, J. E. (2009). Longitudinal study of the transition from healthy aging to Alzheimer disease. Archives of Neurology, 66(10), 1254-1259.
25. Kester, M. I., van der Vlies, A. E., Blankenstein, M. A., Pijnenburg, Y. A. L., van Elk, E. J., Scheltens, P., & van der Flier, W. M. (2009). CSF biomarkers predict rate of cognitive decline in Alzheimer's disease. Neurology, 73, 1353-1358.
26. MacKinnon, D. P., Fairchild, A. J., & Fritz, M. S. (2007). Mediation analysis. Annual Review of Psychology, 58, 593-614.
27. Maxwell, S. E., & Cole, D. A. (2007). Bias in cross-sectional analyses of longitudinal mediation. Psychological Methods, 12(1), 23-44.
28. Mungas, D., Beckett, L., Harvey, D., Tomaszewski Farias, S., Reed, B., Carmichael, O., & Decarli, C. (2010). Heterogeneity of cognitive trajectories in diverse older persons. Psychology and Aging, 25(3), 606-619.
29. Negash, S., Bennett, D. A., Wilson, R. S., Schneider, J. A., & Arnold, S. E. (2011). Cognition and neuropathology in aging: multidimensional perspectives from the rush religious orders study and rush memory and aging project. Current Alzheimer's Research, 8, 336-340.
30. Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D. H., & LaFerla, F. M. (2006). Reduction of the soluable Abeta and tau, but not soluable Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. Journal of Biological chemistry, 281, 39413-39423.
31. Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q., & Weiner, M. W. (2010). Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology, 74, 201-209.
32. Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., & Hardy, J. (2005). Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proceedings of the National Academy of Sciences of the United States of America, 102(23), 8299-8302.
33. Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009). Age, neuropathology, and dementia. The New England Journal of Medicine, 360, 2302-2309.
34. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., & Phelps, C. H. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimer's & Dementia, 7(3), 280-292.
35. Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003). CSF AB42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology, 60, 652-656.
36. Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., Jack, C. R., & On behalf of the Alzheimer's Disease Neuroimaging Initiative. (2009). MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology, 73, 287-293.
37. Verbeke, G., & Molenberghs, G. (2000). Linear mixed models for longitudinal data. New York: Springer.
38. Wilson, R. S., Beckett, L. A., Barnes, L. L., Schneider, J. A., Bach, J., Evans, D. A., & Bennett, D. A. (2002). Individual differences in rates of change in cognitive abilities of older persons. Psychology and Aging, 17(2), 179-193.
39. Yu, B., & Ghosh, P. (2010). Joint modeling for cognitive trajectory and risk of dementia in the presence of death. Biometrics, 66(1), 294-300.